SN Smith & Nephew plc

LSE · GB · Healthcare · Medical Devices · smith-nephew.com

1004.50GBp+1.57%Mkt Cap: 9.14B $P/E: 18.26Today

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three seg…

Industry Peers

Medical Devices

Screen all

ABT

Abbott Laboratories Common Stock

$169.83BUSDP/E 31.6

MDT

Medtronic plc. Ordinary Shares

$110.49BUSDP/E 21.2

SYK

Stryker Corporation Common Stock

$105.65BUSDP/E 28.5

BSX

Boston Scientific Corporation Common Stock

$61.74BUSDP/E 17.2

Edwards Lifesciences Corporation Common Stock

$49.03BUSDP/E 50.7

SHL

Siemens Healthineers AG

$46.06BUSDP/E 19.2

DXCM

DexCom, Inc. - Common Stock

$32.21BUSDP/E 33.7

GEHC

GE HealthCare Technologies Inc. - Common Stock

$29.24BUSDP/E 14.8

PHG

Koninklijke Philips N.V. NY Registry Shares

$23.38BUSDP/E 18.5

PHIA

Koninklijke Philips N.V.

$22.58BUSDP/E 18.5

STE

STERIS plc (Ireland) Ordinary Shares

Zimmer Biomet Holdings, Inc. Common Stock

$16.84BUSDP/E 21.4

PEN

Penumbra, Inc. Common Stock

$12.51BUSDP/E 77.8

TXG

10x Genomics, Inc. - Common Stock

$12.18BUSD

SNN

Smith & Nephew SNATS, Inc. Common Stock

$11.06BUSDP/E 18.0

GMED

Globus Medical, Inc. Class A Common Stock

Bio-Rad Laboratories, Inc. Class A Common Stock

$9.88BUSDP/E 45.0

GKOS

Glaukos Corporation Common Stock

$9.66BUSD

Key Statistics

Company

Market Cap9.14B USD

Enterprise Value12.44B USD

Revenue (TTM)6.85B USD

Gross Profit4.56B USD

Net Income (TTM)679.35M USD

Revenue/Share7.37 GBp

Last Price1004.50 GBp

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees17.0K

CountryGB

SectorHealthcare

IndustryMedical Devices

ISINGB0009223206

Valuation

P/E (Trailing)18.26

P/E (Forward)10.93

PEG1.00

EV/EBITDA8.28

EV/Revenue1.82

P/S1.31

P/B2.15

EPS (TTM)0.55

EPS (Forward)0.90

52W Range

980.405% of range1426.59

52W High1426.59 GBp

52W Low980.40 GBp

Profitability

Gross Margin68.01%

Oper. Margin14.47%

EBITDA Margin21.94%

Profit Margin10.14%

ROE11.82%

ROA5.98%

Growth

Revenue Growth4.60%

Earnings Growth5.70%

Cash Flow & Leverage

Operating CF1.40B USD

CapEx (TTM)470.65M USD

FCF Margin16.81%

FCF Yield12.60%

Net Debt3.29B USD

Net Debt/EBITDA2.19

Balance Sheet

Debt/Equity0.63

Current Ratio2.14

Quick Ratio1.11

Book Value/Sh4.59 GBp

Cash/Share0.89 GBp

Dividends

Fwd Div Rate0.30 GBp

Trail. Div Rate0.40 GBp

Div. Yield2.99%

5Y Avg Yield2.58%

Payout Ratio53.16%

Ex-Div DateOct 1, 2026

Pay Date—

Splits

Last Split9:11

Split DateAug 7, 2000

Analyst Consensus

Rating2.7 (Hold)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)1279.04 GBp

Upside (mean)+27.3%

Target Range1068.45 GBp – 1569.12 GBp

1068.45+27.3% to mean1569.12

# Analysts17

Ownership

Shares Out.837.03M

Float842.20M

Insiders0.24%

Institutions74.83%

Technical

SMA 501071.53 (-6.3%)

SMA 2001166.94 (-13.9%)

Beta0.68

S&P 52W Chg14.58%

Avg Vol (30d)2.77M

Avg Vol (10d)2.64M

Technical Indicators

RSI (14)33.8

MACD-23.1868

MACD Signal-22.1747

MACD Hist.-1.0121

BB Upper1070.55 GBp

BB Middle1024.70 GBp

BB Lower978.84 GBp

BB Width8.95%

ATR (14)22.67 GBp

Vol Ratio (20d)1.01x